bonus ph365 。

With more than half of the 16 teams still mathematically alive to make the conference championship game, the Big 12 will command a lot of attention in the final week of the regular season. No. 14 Arizona State and No. 17 Iowa State would play for the Big 12 title and likely College Football Playoff spot on Dec. 7 if they both win Saturday and there's a four-way tie for first place. There are seven other teams that begin this week with hopes, slim in most cases, of getting into the game at AT&T Stadium in Arlington, Texas. Last week it was No. 19 BYU and No. 23 Colorado that had the inside track to the championship game. Arizona State beat the Cougars and Kansas knocked off the Buffaloes, and here we are. "Everybody counted us out, I think, two weeks ago," Iowa State coach Matt Campbell said after his team beat Utah 31-28. "We didn't flinch. We didn't waver. And we just keep fighting." The Cyclones were national darlings the first half of the season as they won seven straight games to match the best start in program history. Back-to-back losses to Texas Tech and Kansas followed. Now they've won two straight heading into "Farmageddon," their rivalry game against Kansas State at home. "Right now they've got the pen and they continue to write the story," Campbell said of his players, "and I hope they will continue to write it the way they've got the ability to write it. Unwavering. Tough, mentally tough, physically tough. This group has stood for it every step of the way." Arizona State has been an even better story than the Cyclones. The Sun Devils have six more wins than they did last season, when they went 3-9. They were picked to finish last in their first year in the Big 12. They'll go for their fifth straight victory when they play at Arizona on Saturday. "These guys came off no momentum and everybody doubting them, and everybody is still doubting them. That's what makes this special," second-year coach Kenny Dillingham said. "Hopefully the expectations become higher. I don't know if there's a way we can exceed expectations more than we're exceeding them right now." Checking in on five of the Top 25: The Ducks were idle Saturday after clinching a spot in the Big Ten championship game with their win at Wisconsin on Nov. 16. Oregon can go 12-0 in the regular season for the first time since 2010 if it beats Washington at home this week. Oregon's only two losses last season came against the Huskies, both decided by three points. The first was a top-10 matchup in the regular season and the second was a top-five matchup in the Pac-12 championship game. The Ducks are 19 1/2-point favorites this time, according to BetMGM Sportsbook. The Buckeyes' showdown with upstart Indiana combined with Michigan's dropoff after winning the national championship have lowered the volume on this week's meeting with the Wolverines at the Horseshoe. If Michigan beats Ohio State a fourth straight time and it keeps the Buckeyes out of the Big Ten championship game and playoff ... well, there'll be lots of noise in Columbus then. The Lone Star Showdown returns to the gridiron for the first time since 2011, when Texas and Texas A&M were in the Big 12. The Longhorns head to No. 20 Texas A&M on a four-game win streak. The Aggies have lost two of three after Saturday's four-overtime loss at Auburn. The winner advances to the Southeastern Conference championship game against Georgia. The Broncos are tied with Notre Dame for the second-longest active win streak, at nine games, and they seem to have adopted a survive-and-advance mantra. They trailed 23-point underdog Wyoming in the fourth quarter before winning 17-13 and clinching a spot in the Mountain West championship game. They won their previous game, 42-21 against San Jose State, but didn't pull away until the fourth quarter. Two weeks ago they beat a three-win Nevada team 28-21. Just when you think Illinois is about to cash in for the season, they do what they did against Rutgers. The Illini were down 31-30 when they lined up for a 58-yard field goal with 14 seconds left. Ethan Moczulski missed. But wait. Rutgers called timeout before the snap, and Bret Bielema thought better of trying another kick and sent his offense back on the field. Luke Altmyer passed to Pat Bryant for the winning 40-yard touchdown. The Illini won't play for the Big Ten title, but they have a chance for nine wins and a nice bowl. Ohio State played in three of the five regular-season top-five matchups and won three of them. The Buckeyes lost to Oregon and beat Penn State and Indiana. ... Kansas' 37-21 win over Colorado made the Jayhawks the first FBS team with a losing record to beat three straight Top 25 opponents. The Jayhawks, who were 2-6 a month ago, will be bowl eligible if they win at Baylor. ... Nebraska ended the longest power conference bowl drought with its 44-25 win over Wisconsin. The Cornhuskers haven't played in a bowl since 2016. Be the first to know Get local news delivered to your inbox!

AI has been a boon for marketing, but the dark side of using algorithms to sell products and brands is little studied

No. 14 ASU, No. 17 Iowa State front-runners for possibly wild Big 12 finishThe rapid rise and fall of Lauren Boebert’s Cameo page

Uncovering the richness of African locust bean in traditional cooking

Donald Trump promises ‘unity’ in preview of inaugural address

Transform Holiday Leftovers into Vibrant, Flavorful MealsMultifunctional Waterproof Drone Market Poised for Growth with Expanding Applications in Industrial and Commercial Sectors | Valuates Reports 12-08-2024 06:55 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Valuates Reports Multifunctional Waterproof Drone Market The global Multifunctional Waterproof Drone market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-25W12807/Global_Multifunctional_Waterproof_Drone_Market_Research_Report_2023 Major Trends: 1.Integration of Advanced Sensors: The integration of high-performance sensors, such as thermal, LiDAR, and HD cameras, is driving multifunctional waterproof drones' ability to operate in diverse environments, including search and rescue, surveillance, and agriculture. 2.Increased Use in Harsh Environments: These drones are becoming increasingly popular in industries such as marine, oil and gas, and disaster management, where drones are required to operate in wet or hazardous conditions, supporting a wider range of applications. 3.Technological Advancements in Battery Life: Improved battery technology is enabling longer flight times, which is essential for industries such as agriculture, mapping, and infrastructure inspections, where drones need extended operational periods. 4.Growth in Environmental and Agriculture Applications: Waterproof drones are increasingly being used in precision agriculture, environmental monitoring, and conservation efforts, where weatherproof capabilities are crucial for collecting data in challenging outdoor conditions. 5.Regulatory Advancements: As regulatory frameworks for drones evolve, there is a greater focus on safety standards, airspace management, and commercial use, enabling more widespread deployment of multifunctional waterproof drones in various industries. Challenges: 1.High Cost of Drones: Multifunctional waterproof drones often come with higher price tags due to their advanced technology and materials, which may limit adoption in certain markets, especially for small businesses. 2.Limited Battery Life: While battery life is improving, drones still face limitations when it comes to long-duration flights. Extended flight times are critical for commercial applications, such as surveying large areas. By Type •Silicone Waterproofing •Acrylic Waterproofing By Application •Commercial •Military Key Companies Swellpro, LiDiRC, DIODON Drone Technology, GPTOYS, Autel Robotics, JJRC View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-25W12807/global-multifunctional-waterproof-drone Please reach us at sales@valuates.com Address: Valuates, 4th Floor, Balaraj's Arcade, Whitefield Main road, Bangalore 560066 Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends. This release was published on openPR.

- Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”), a prominent player in stem cell therapies and regenerative medicine, to form a joint venture. Guangdong Cell Biotech develops autologous cell treatments and tailored medicines for various disorders. This potential collaboration aims to leverage the complementary strengths of both companies to accelerate growth and innovation across the biotechnology and consumer health sectors. Discussions are focused on leveraging EUDA’s digital healthcare ecosystem as a platform to deliver cutting-edge regenerative therapies developed by Guangdong Cell Biotech to a broader audience in Southeast Asia. Guangdong Cell Biotech’s stem cell technology is expected to enrich EUDA’s healthcare services with innovative treatment options, enhancing the appeal and effectiveness of its digital platform. Guangdong Cell Biotech represents that it currently has 37 established stem cell and DNA medical treatment facilities in China and presence in Indonesia and Cambodia. A joint venture combining EUDA’s expertise in making holistic healthcare solutions accessible to everyone using its portfolio of products and advanced technologies, with Guangdong Cell Biotech’s leadership in stem cell treatment, will allow EUDA to enhance its market presence, improve product offerings, and deliver cutting-edge solutions to customers in Asia. Strategic Rationale The potential strategic partnership between EUDA and Guangdong Cell Biotech aims to: “We are excited about the opportunity to collaborate with Guangdong Cell Biotech,” said Kelvin Chen, CEO of EUDA. “While our discussions are in the early stages, we are optimistic about the potential to combine our strengths in offering non-invasive, holistic wellness consumer products through our ecosystem, with Guangdong Cell Biotech’s established 30+ stem cell and DNA medical treatment facilities, further diversifying our healthcare ecosystem and revenue streams going forward.” Wang Taihua, Founder and Chairman of Guangdong Cell Biotech, added, “This potential partnership reflects our shared vision of driving innovation and expanding the impact we have on wellness consumers in Asia. The market for stem cell treatment in China and across Asia is massive, and we look forward to exploring this opportunity and evaluating how we can transform the industry together.” Parties have not entered into a letter of intent or a legally binding agreement at this time. There is no guarantee that parties will form a joint venture or enter into a definitive written agreement to collaborate in the future. About EUDA Health Holdings Limited EUDA Health Holdings Limited is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, and improving the patient experience by delivering better outcomes through personalized healthcare. The company’s proprietary unified AI platform quickly assesses a patient’s medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. EUDA Health’s holistic approach supports patients throughout all stages of care, including wellness & prevention, urgent care & emergencies, pre-existing conditions, and aftercare services. About Guangdong Cell Biotech Co. Ltd. Guangdong Cell Biotech Co. Ltd and its subsidiaries is a leading enterprise and backbone enterprise in the field of stem cell and regenerative medicine in China. The group has established three platforms of stem cell regenerative medicine, immune cell rehabilitation medicine and genomics, covering the field stem cell drug research, clinical research and transformation services, adult cell storage business, CAR-T immune cell products, and research and development of new cell derivative product. They have currently more than 70 invention patents and 3 international invention patents. The group now have over 30 branches and subsidies home and abroad, and cooperates intensively with more than 100 well-known research institutes and clinical institutes. Forward Looking Statements This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. sYou should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Guangdong Cell Biotech, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. As parties have only entered into preliminary discussions at this time, they have not entered into any definitive legally binding agreement. There is also no guarantee that parties will form a joint venture or enter into a definitive written agreement to collaborate. The execution of a definitive agreement will be disclosed by EUDA. Contact: Christensen Advisory Roger Hu 852.2232.3968 roger.hu@christensencomms.com

BOSTON--(BUSINESS WIRE)--Dec 8, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVYTM (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additional evidence of the benefits of eradicating transfusion requirements for people with transfusion-dependent beta thalassemia and vaso-occlusive crises for those with sickle cell disease,” said Franco Locatelli, M.D., Ph.D., Professor of Pediatrics at the Catholic University of the Sacred Heart of Rome, Director of the Department of Pediatric Hematology and Oncology at Bambino Gesù Children’s Hospital, Chair of Vertex’s TDT Program Steering Committee, and Presenting Author of the CASGEVY clinical data at ASH. “With median follow-up around three years there is strong evidence for the durability of these beneficial effects following treatment with CASGEVY.” “CASGEVY is changing the outlook for people living with sickle cell disease and beta thalassemia, with these data reinforcing the immense clinical value a durable one-time therapy can provide to patients,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “We have a strong commitment to build on our progress in bringing CASGEVY to patients around the world.” New long-term follow-up data presented from the CASGEVY trials Vertex had seven abstracts accepted at the ASH annual meeting as outlined below: Progress in bringing CASGEVY to patients around the world CASGEVY is approved for both SCD and TDT in the U.S., the European Union, Great Britain, Canada, Switzerland, Bahrain and the Kingdom of Saudi Arabia, and Vertex plans to make submissions in the United Arab Emirates and Kuwait. More than 45 authorized treatment centers have been activated globally to support the delivery of CASGEVY, and more than 40 patients have had a first cell collection. Vertex is continuing to work with reimbursement authorities to secure sustainable access for patients. Through this work, Vertex has agreements to provide CASGEVY in multiple countries, including the U.S., England (TDT), Austria, Bahrain and the Kingdom of Saudi Arabia, and continues to make strong progress in others, including positive Health Technology Assessments (HTAs) in Canada for both diseases and advancing access negotiations for SCD patients in England. In the U.S., Vertex recently secured an industry-first, voluntary agreement with the Centers for Medicare & Medicaid Services (CMS) on a single outcomes-based arrangement available to all state Medicaid programs to ensure broad and equitable access to CASGEVY. To support this progress on patient access and growing patient demand, Vertex has received approval for a third manufacturing facility for CASGEVY with our partner Lonza. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive and life-shortening disease. SCD patients report health-related quality of life scores well below the general population, and the lifetime health care costs in the U.S. of managing SCD for patients with recurrent VOCs is estimated between $4 and $6 million. SCD is an inherited blood disorder that affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or “sickled” red blood cells. The clinical hallmark of SCD is VOCs, which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires a lifetime of treatment and results in a reduced life expectancy. In the U.S., the median age of death for patients living with SCD is approximately 45 years. A cure for SCD today is a stem cell transplant from a matched donor, but this option is only available to a small fraction of patients living with SCD because of the lack of available donors. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and the lifetime health care costs in the U.S. of managing TDT are estimated between $5 and $5.7 million. TDT requires frequent blood transfusions and iron chelation therapy throughout a person’s life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. In the U.S., the median age of death for patients living with TDT is 37 years. Stem cell transplant from a matched donor is a curative option but is only available to a small fraction of people living with TDT because of the lack of available donors. About CASGEVYTM (exagamglogene autotemcel [exa-cel]) CASGEVYTM is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CASGEVY (exagamglogene autotemcel) WHAT IS CASGEVY? CASGEVY is a one-time therapy used to treat people aged 12 years and older with: • sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs • beta thalassemia (β-thalassemia) who need regular blood transfusions CASGEVY is made specifically for each patient, using the patient’s own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF). Having more HbF increases overall hemoglobin levels and has been shown to improve the production and function of red blood cells. This can eliminate VOCs in people with sickle cell disease and eliminate the need for regular blood transfusions in people with beta thalassemia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about CASGEVY? After treatment with CASGEVY, you will have fewer blood cells for a while until CASGEVY takes hold (engrafts) into your bone marrow. This includes low levels of platelets (cells that usually help the blood to clot) and white blood cells (cells that usually fight infections). Your doctor will monitor this and give you treatment as required. The doctor will tell you when blood cell levels return to safe levels. You may experience side effects associated with other medicines administered as part of the treatment regimen for CASGEVY. Talk to your physician regarding those possible side effects. Your healthcare provider may give you other medicines to treat your side effects. How will I receive CASGEVY? Your healthcare provider will give you other medicines, including a conditioning medicine, as part of your treatment with CASGEVY. It’s important to talk to your healthcare provider about the risks and benefits of all medicines involved in your treatment. After receiving the conditioning medicine, it may not be possible for you to become pregnant or father a child. You should discuss options for fertility preservation with your healthcare provider before treatment. STEP 1: Before CASGEVY treatment, a doctor will give you mobilization medicine(s). This medicine moves blood stem cells from your bone marrow into the blood stream. The blood stem cells are then collected in a machine that separates the different blood cells (this is called apheresis). This entire process may happen more than once. Each time, it can take up to one week. During this step rescue cells are also collected and stored at the hospital. These are your existing blood stem cells and are kept untreated just in case there is a problem in the treatment process. If CASGEVY cannot be given after the conditioning medicine, or if the modified blood stem cells do not take hold (engraft) in the body, these rescue cells will be given back to you. If you are given rescue cells, you will not have any treatment benefit from CASGEVY. STEP 2: After they are collected, your blood stem cells will be sent to the manufacturing site where they are used to make CASGEVY. It may take up to 6 months from the time your cells are collected to manufacture and test CASGEVY before it is sent back to your healthcare provider. STEP 3: Shortly before your stem cell transplant, your healthcare provider will give you a conditioning medicine for a few days in hospital. This will prepare you for treatment by clearing cells from the bone marrow, so they can be replaced with the modified cells in CASGEVY. After you are given this medicine, your blood cell levels will fall to very low levels. You will stay in the hospital for this step and remain in the hospital until after the infusion with CASGEVY. STEP 4: One or more vials of CASGEVY will be given into a vein (intravenous infusion) over a short period of time. After the CASGEVY infusion, you will stay in hospital so that your healthcare provider can closely monitor your recovery. This can take 4-6 weeks, but times can vary. Your healthcare provider will decide when you can go home. What should I avoid after receiving CASGEVY? What are the possible or reasonably likely side effects of CASGEVY? The most common side effects of CASGEVY include: Your healthcare provider will test your blood to check for low levels of blood cells (including platelets and white blood cells). Tell your healthcare provider right away if you get any of the following symptoms: These are not all the possible side effects of CASGEVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of CASGEVY Talk to your healthcare provider about any health concerns. Please see full Prescribing Information including Patient Information for CASGEVY. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn , Facebook , Instagram , YouTube and X . (VRTX-GEN) Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Franco Locatelli, M.D., Ph.D. and Carmen Bozic, M.D., in this press release, and statements regarding expectations for the anticipated transformative, durable clinical benefits of CASGEVY, plans to continue working with reimbursement authorities to secure sustainable access for patients, including our expectations for progress in Canada and England, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com . You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. View source version on businesswire.com : https://www.businesswire.com/news/home/20241206536804/en/ CONTACT: Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.comMedia : mediainfo@vrtx.com or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS SOURCE: Vertex Pharmaceuticals Incorporated Copyright Business Wire 2024. PUB: 12/08/2024 12:52 PM/DISC: 12/08/2024 12:50 PM http://www.businesswire.com/news/home/20241206536804/en Copyright Business Wire 2024.Cal selected to play in LA Bowl later this month